Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1528-1539
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1528
Table 2 List of gene fusions involving targetable genes in Chinese patients with gastric cancer and drugs under clinical trial or approved by the Food and Drug Administration
Patients ID
Fusion gene
5' partner gene
3' partner gene
Variant frequency, %
Functional domain is included or not
Targeted drugs
Gene name
Chromosome
Last observed exon
Breakpoint
Gene name
Chromosome
First observed exon
Breakpoint
Patient 01RARA-PGAP3RARA17338504951PGAP31783782802024.1Partially includeTamibarotene targeting RARA fusion2
Patient 01KRTAP9-7-RARAKRTAP9-717downstream39437039RARA1733849954756.9Completely includeTamibarotene targeting RARA fusion2
Patient 02RARA-KRT13RARA17238491648KRT131783965726929.2Partially includeTamibarotene targeting RARA fusion2
Patient 02RARA-ETV4RARA17238499726ETV41754162124376Partially includeTamibarotene targeting RARA fusion2
Patient 03RARA-IKZF3RARA17238504120IKZF31723800955518.4Partially includeTamibarotene targeting RARA fusion2
Patient 04FGFR2-PDE2AFGFR21017123241248PDE2A117723072511.4Completely includePemigatinib; Erdafitinib targeting FGFR fusion1
Patient 05FGFR2-intergenicFGFR21017123242196intergenic10-12339410716.6Completely includePemigatinib; Erdafitinib targeting FGFR fusion1
Patient 06FGFR2-intergenicFGFR21017123240841intergenic10-1227938424.2Completely includePemigatinib; Erdafitinib targeting FGFR fusion1
Patient 07FGFR2-SHTN1FGFR21017123242528SHTN11061187093055.1Completely includePemigatinib; Erdafitinib targeting FGFR fusion1
Patient 08FGFR3-PHTF2FGFR34181808927PHTF2711775679823.3Completely includePemigatinib; Erdafitinib targeting FGFR fusion1
Patient 09STIM2-BRAFSTIM241127012641BRAF7914048792912.7Completely includeSelumetinib targeting BRAF fusion1
Patient 09STIM2-BRAFSTIM241127013243BRAF7101404861031.1Completely includeSelumetinib targeting BRAF fusion1
Patient 09TBC1D19-BRAFTBC1D194426629603BRAF7101404867826.5Completely includeSelumetinib targeting BRAF fusion1
Patient 10TES-METTES71115867013MET721163322270.7Completely includeCrizotinib targeting MET fusion1
Patient 11MET-TESMET721116436166TES7411588944524.6Not includeCrizotinib targeting MET fusion1
Patient 12EML4-ALKEML42629447382ALK220424986623.5Completely includeCrizotinib; ceritinib targeting ALK fusion1
Patient 13OPALIN-RETOPALIN10698104545RET1011436100995.46Completely includePralsetinib targeting RET fusion1
Patient 14ARHGAP10-NTRK2ARHGAP1041148716754NTRK29168747664515.3Completely includeLarotrectinib targeting NTRK2 fusion1
Patient 15NRG1-FDFT1NRG181232617907FDFT188116853758.9Partially includeMCLA-128 targeting NRG1 fusion2
Patient 16EGFR-SEPTIN14EGFR72555269173SEPTIN14710558711799.6Completely includeAfatinib targeting EGFR fusion2